1. Jerums G., Panagiotopoulos S., Premaratne E., MacIsaac R.J.. Integrating albuminuria and GFR in the assessment of diabetic nephropathy.
Nat Rev Nephrol 5:2009;397–406.
2. Tseng C.H.. Mortality and causes of death in a national sample of diabetic patients in Taiwan.
Diabetes Care 27:2004;1605–1609.
4. Tervaert T.W., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B., Ferrario F., Fogo A.B., Haas M., de Heer E., Joh K., Noël L.H., Radhakrishnan J., Seshan S.V., Bajema I.M., Bruijn J.A.. Renal Pathology Society: Pathologic classification of diabetic nephropathy.
J Am Soc Nephrol 21:2010;556–563.
5. Powell D.W., Kenagy D.N., Zheng S., Coventry S.C., Xu J., Cai L., Carlson E.C., Epstein P.N.. Associations between structural and functional changes to the kidney in diabetic humans and mice.
Life Sci 93:2013;257–264.
6. http://www.kidney.org/atoz/pdf/diabetes.pdf.
7. N Engl J Med.
8. Lancet.
9. Thomas M.C., Groop P.H., Tryggvason K.. Towards understanding the inherited susceptibility for nephropathy in diabetes.
Curr Opin Nephrol Hypertens 21:2012;195–202.
10. Berger M., Mönks D., Wanner C., Lindner T.H.. Diabetic nephropathy: an inherited disease or just a diabetic complication?
Kidney Blood Press Res 26:2003;143–154.
11. Ravera M., Re M., Deferrari L., Vettoretti S., Deferrari G.. Importance of blood pressure control in chronic kidney disease.
J Am Soc Nephrol 17:2006;S98–S103.
12. Chakkarwar V.A.. Smoking in diabetic nephropathy: sparks in the fuel tank?
World J Diabetes 3:2012;186–195.
13. Takao T., Matsuyama Y., Yanagisawa H., Kikuchi M., Kawazu S.. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes.
J Diabetes Complications 28:2014;185–190.
14. Toto R.D.. Treatment of hypertension in chronic kidney disease.
Semin Nephrol 25:2005;435–439.
16. Ha H., Yu M.R., Choi Y.J., Lee H.B.. Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney.
Am J Kidney Dis 38:2001;S204–S207.
17. Vlassara H., Palace M.R.. Diabetes and advanced glycation endproducts.
J Intern Med 251:2002;87–101.
18. Kulkarni S., O׳Farrell I., Erasi M., Kochar M.S.. Stress and hypertension. WMJ 97:1998;34–38.
19. Heraclides A., Chandola T., Witte D.R., Brunner E.J.. Psychosocial stress at work doubles the risk of type 2 diabetes in middle-aged women: evidence from the Whitehall II study.
Diabetes Care 32:2009;2230–2235.
20. Hanson C.L., Henggeler S.W., Burghen G.A.. Model of associations between psychosocial variables and health-outcome measures of adolescents with IDDM.
Diabetes Care 10:1987;752–758.
21. Brody M.J., Natelson B.H., Anderson E.A., Folkow B., Levy M.N., Obrist P.A., Reis D.J., Rosenman R.H., Williams R.B. Jr. Behavioral mechanisms in hypertension.
Circulation 76:1987;I95–I100.
22. Cohen S., Herbert T.B.. Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology.
Annu Rev Psychol 47:1996;113–142.
23. Rod N.H., Grønbaek M., Schnohr P., Prescott E., Kristensen T.S.. Perceived stress as a risk factor for changes in health behaviour and cardiac risk profile: a longitudinal study.
J Intern Med 266:2009;467–475.
24. Pollard T.M.. Physiological consequences of everyday psychosocial stress.
Coll Antropol 21:1997;17–28.
25.
26. Marmot M., Wilkinson R.. Social Determinants of Health. 2nd edition. 2005. Oxford University Press; Oxford.
27. Mykletun A., Overland S., Aarø L.E., Liabø H.M., Stewart R.. Smoking in relation to anxiety and depression: evidence from a large population survey: the HUNT study.
Eur Psychiatry 23:2008;77–84.
28. Saravanan C., Heidhy I.. Psychological problems and psychosocial predictors of cigarette smoking behavior among undergraduate students in Malaysia.
Asian Pac J Cancer Prev 15:2014;7629–7634.
29. Surwit R.S., van Tilburg M.A., Zucker N., McCaskill C.C., Parekh P., Feinglos M.N., Edwards C.L., Williams P., Lane J.D.. Stress management improves long-term glycemic control in type 2 diabetes.
Diabetes Care 25:2002;30–34.
30. Zoppini G., Targher G., Chonchol M., Ortalda V., Negri C., Stoico V., Bonora E.. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function.
Clin J Am Soc Nephrol 7:2012;401–408.
31. Lorenzo V., Saracho R., Zamora J., Rufino M., Torres A.. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria.
Nephrol Dial Transplant 25:2010;835–841.
32. Yokoyama H., Kanno S., Takahashi S., Yamada D., Itoh H., Saito K., Sone H., Haneda M.. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension.
Clin J Am Soc Nephrol 4:2009;1432–1440.
33.
34. Roblin D.W.. Validation of a neighborhood SES index in a managed care organization.
Med Care 51:2013;e1–e8.
35. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D.. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann Intern Med 130:1999;461–470.
36. SAS, Base SAS 9.3. Procedures Guide. 2011. SAS Institute Inc; Cary, NC.
37. Muthén L.K., Muthén B.O.. Mplus User׳s Guide. 6th edition.1998–2010. Muthén & Muthén; Los Angeles, CA.
38. Rifkin D.E., Shlipak M.G., Katz R., Fried L.F., Siscovick D., Chonchol M., Newman A.B., Sarnak M.J.. Rapid kidney function decline and mortality risk in older adults.
Arch Intern Med 168:2008;2212–2218.
39. Matsushita K., Selvin E., Bash L.D., Franceschini N., Astor B.C., Coresh J.. Change in estimated GFR associates with coronary heart disease and mortality.
J Am Soc Nephrol 20:2009;2617–2624.
40. N Engl J Med.
41. Tsurugano S., Nakao M., Takeuchi T., Nomura K., Yano E.. Job stress strengthens the link between metabolic risk factors and renal dysfunction in adult men.
Tohoku J Exp Med 226:2012;101–108.
43. Mendenhall E., Shivashankar R., Tandon N., Ali M.K., Narayan K.M., Prabhakaran D.. Stress and diabetes in socioeconomic context: a qualitative study of urban Indians.
Soc Sci Med 75:2012;2522–2529.
44. Pascoe E.A., Smart Richman L.. Perceived discrimination and health: a meta-analytic review.
Psychol Bull 135:2009;531–554.
45. Glassock R.J., Winearls C.. Ageing and the glomerular filtration rate: truths and consequences.
Trans Am Clin Climatol Assoc 120:2009;419–428.
46. Sarnak M.J., Levey A.S.. Cardiovascular disease and chronic renal disease: a new paradigm.
Am J Kidney Dis 35:2000;S117–S131.
47. Perkins R.M., Bucaloiu I.D., Kirchner H.L., Ashouian N., Hartle J.E., Yahya T.. GFR decline and mortality risk among patients with chronic kidney disease.
Clin J Am Soc Nephrol 6:2011;1879–1886.
48. Goel G., Perkins B.A.. Can improved glycemic control slow renal function decline at all stages of diabetic nephropathy?
Semin Nephrol 32:2012;423–431.
49. JAMA.
50. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., Krolewski A.S.. Regression of microalbuminuria in type 1 diabetes.
N Engl J Med 348:2003;2285–2293.
51. Araki S., Haneda M., Sugimoto T., Isono M., Isshiki K., Kashiwagi A., Koya D.. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes.
Diabetes 54:2005;2983–2987.
52. Torén K., Schiöler L., Giang W.K., Novak M., Söderberg M., Rosengren A.. A longitudinal general population-based study of job strain and risk for coronary heart disease and stroke in Swedish men.
BMJ Open 4:2014;e004355.
54. Slama-Chaudhry A., Schaller P., Raetzo M.A., Gaspoz J.M.. Chronic diseases and integrated health care delivery system: the example of Kaiser Permanente.
Rev Med Suisse 4:2008;2040–2043.
55. Derose S.F., Rutkowski M.P., Crooks P.W., Shi J.M., Wang J.Q., Kalantar-Zadeh K., Kovesdy C.P., Levin N.W., Jacobsen S.J.. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system.
Am J Kidney Dis 62:2013;236–244.
56. Hsu C.Y., Lin F., Vittinghoff E., Shlipak M.G.. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States.
J Am Soc Nephrol 14:2003;2902–2907.
57. Ringborg A., Lindgren P., Yin D.D., Martinell M., Stålhammar J.. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes.
Diabetes Metab 36:2010;198–203.
58. Philis-Tsimikas A.. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control.
Am J Med 126:2013;S21–S27.
59. Machado-Alba J.E., Machado-Duque M.E., Moreno-Gutierrez P.A.. Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus.
Diabetes Res Clin Pract 107:2015;332–337.
60. Fontela P.C., Winkelmann E.R., Ott J.N., Uggeri D.P.. Estimated glomerular filtration rate in patients with type 2 diabetes mellitus.
Rev Assoc Med Bras 60:2014;531–537.
61. Rossing K., Christensen P.K., Hovind P., Tarnow L., Rossing P., Parving H.H.. Progression of nephropathy in type 2 diabetic patients.
Kidney Int 66:2004;1596–1605.
62. Nelson R.G., Bennett P.H., Beck G.J., Tan M., Knowler W.C., Mitch W.E., Hirschman G.H., Myers B.D.. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group.
N Engl J Med 335:1996;1636–1642.
63. Brenner B.M., Cooper M.E.. de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 345:2001;861–869.
64. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., de Zeeuw D., Shahinfar S., Toto R., Levey A.S.; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Ann Intern Med 139:2003;244–252.
65. Bollen K.A.. Structural equations with latent variables. Wiley series in probability and mathematical statistics Applied probability and statistics. 1989. Wiley; New York.
66. nd.